Posted by Michael Wonder on 29 Sep 2016
NICE rejects LIlly's Portrazza
28 September 2016 - NICE is not in favour of the use of Portrazza on the NHS.
On September 28 2016, NICE published guidance not recommending the use of necitumumab in combination with gemcitabine and cisplatin for the treatment of patients with untreated advanced or metastatic EGFR-expressing, squamous non-small-cell lung cancer.
